Shortened Fingers and Toes: GNAS Abnormalities are Not the Only Cause

Abstract

The PTH/PTHrP receptor (PTHR1) mediates the actions of parathyroid hormone (PTH) and PTH-related peptide (PTHrP) by coupling this G protein-coupled receptor (GPCR) to the alpha-subunit of the heterotrimeric stimulatory G protein (Gsα) and thereby to the formation of cAMP. In growth plates, PTHrP-dependent activation of the cAMP/PKA second messenger pathway prevents the premature differentiation of chondrocytes into hypertrophic cells resulting in delayed growth plate closure. Heterozygous mutations in GNAS, the gene encoding Gsα, lead to a reduction in cAMP levels in growth plate chondrocytes that is sufficient to cause shortening of metacarpals and/or -tarsals, i. e. typical skeletal aspects of Albright’s Hereditary Osteodystrophy (AHO). However, heterozygous mutations in other genes, including those encoding PTHrP, PRKAR1A, PDE4D, and PDE3A, can lead to similar or even more pronounced acceleration of skeletal maturation that is particularly obvious in hands and feet, and reduces final adult height. Genetic mutations other than those resulting in Gsα haploinsufficiency thus reduce intracellular cAMP levels in growth plate chondrocytes to a similar extent and thereby accelerate skeletal maturation.

Key words

PTH - PTHrP - PTH/PTHrP receptor - GNAS - alpha-subunit of the stimulatory G protein - genetic disease - acrodysostosis - cAMP signaling pathway - PRKAR1A - PDE4D - PDE3A - HDAC4

Publikationsverlauf

Eingereicht: 08. Oktober 2019
Eingereicht: 08. Oktober 2019

Angenommen: 06. November 2019

Artikel online veröffentlicht:
11. Dezember 2019

• References

• 1 Potts JT Jr., Gardella TJ. Progress, paradox, and potential: Parathyroid hormone research over five decades. Ann NY Acad Sci 2007; 1117: 196-208
• 2 Suva LJ, Freeman A, Martin TJ. Eds Parathyroid hormone-related protein: Gene structure, biosynthesis, metabolism and regulation. San Diego: Adademic Press; 2015: 45-64
• 3 Maes C, Kronenberg HM. In: DeGroot LJ, and Jameson JL Eds Endocrinology. Philadelphia, PA: W.B. Saunders Company; 2016: 1038-1062
• 4 Gardella TJ, Jüppner H, Brown EM. et al. In: DeGroot LJ, and Jameson JL, Eds Endocrinology. Philadelphia, PA: W.B. Saunders Company; 2016: 969-990
• 5 Wein MN. Parathyroid hormone signaling in osteocytes. JBMR Plus 2018; 2: 22-30
• 6 Wein MN, Foretz M, Fisher DE. et al. Salt-inducible kinases: Physiology, regulation by cAMP, and therapeutic potential: (Trends Endocrinol. Metab. 29, 723-735, 2018).. Trends Endocrinol Metab 2019; 30: 407
• 7 Albright F, Burnett CH, Smith PH. et al. Pseudohypoparathyroidism - an example of “Seabright-Bantam syndrome”. Endocrinology. 1942; 30: 922-932
• 8 Chase LR, Aurbach GD. Parathyroid function and the renal excretion of 3'5'-adenylic acid. Proc Natl Acad Sci USA 1967; 58: 518-525
• 9 Chase LR, Fedak SA, Aurbach GD. Activation of skeletal adenyl cyclase by parathyroid hormone in vitro. Endocrinology 1969; 84: 761-768
• 10 Chase LR, Aurbach GD. The effect of parathyroid hormone on the concentration of adenosine 3',5'-monophosphate in skeletal tissue in vitro. J Biol Chem 1970; 245: 1520-1526
• 11 Marcus R, Aurbach GD. Adenyl cyclase from renal cortex. Biochim Biophys Acta 1971; 242: 410-421
• 12 Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: Defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969; 48: 1832-1844
• 13 Levine MA, Downs RW, Singer M. et al. Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem Biophys Res Commun 1980; 94: 1319-1324
• 14 Farfel Z, Brickman AS, Kaslow HR. et al. Defect of receptor-cyclase coupling protein in pseudohypoparathyroidism. N Engl J Med 1980; 303: 237-242
• 15 Linglart A, Carel JC, Garabedian M. et al. GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: Genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J Clin Endocrinol Metab 2002; 87: 189-197
• 16 Levine MA. In: JP Bilezikian LR, GA. Rodan ed Principles of Bone biology. New York: Academic Press; 2002: 1137-1159
• 17 Bastepe M, Jüppner H. In: DeGroot LJ, and Jameson JL, Eds Endocrinology. Philadelphia, PA: W.B. Saunders Company; 2016: 1147-1159
• 18 Linglart A, Maupetit-Mehouas S, Silve C. GNAS -related loss-of-function disorders and the role of imprinting. Horm Res Paediatr 2013; 119-129
• 19 Elli FM, Linglart A, Garin I. et al. The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP Network. J Clin Endocrinol Metab 2016; 101: 3657-3668
• 20 Albright F, Forbes AP, Henneman PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952; 65: 337-350
• 21 Shore E, Ahn J, Jan de Beur S. et al. Paternally-inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. New Engl J Med 2002; 346: 99-106
• 22 Patten JL, Johns DR, Valle D. et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright’s hereditary osteodystrophy. New Engl J Med 1990; 322: 1412-1419
• 23 Weinstein LS, Gejman PV, Friedman E. et al. Mutations of the Gs a-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1990; 87: 8287-8290
• 24 Tafaj O, Jüppner H. Pseudohypoparathyroidism: One gene, several syndromes. J Endocrinol Invest 2017; 40: 347-356
• 25 Mantovani G, Bastepe M, Monk D. et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: First International Consensus Statement. Nat Rev Endocrinol 2018; 14: 476-500
• 26 Davies SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. J Med Genet 1993; 30: 101-103
• 27 Long DN, McGuire S, Levine MA. et al. Body mass index differences in pseudohypoparathyroidism type 1a vs. pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J Clin Endocrinol Metab 2007; 92: 1073-1079
• 28 Schipani E, Weinstein LS, Bergwitz C. et al. Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin Endocrinol Metab 1995; 80: 1611-1621
• 29 Bastepe M, Lane AH, Jüppner H. Paternal uniparental isodisomy of chromosome 20q (patUPD20q) - and the resulting changes in GNAS1 methylation - as a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 2001; 68: 1283-1289
• 30 Mantovani G, Bondioni S, Linglart A. et al. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2007; 92: 3738-3742
• 31 Sharma A, Phillips AJ, Jüppner H. Hypoplastic metatarsals–beyond cosmesis. N Engl J Med 2015; 373: 2189-2190
• 32 Sanchez J, Perera E, Jan de Beur S. et al. Madelung-like deformity in pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab 2011; 96: E1507-E1511
• 33 Mundlos S. The brachydactylies: A molecular disease family. Clin Genet 2009; 76: 123-136
• 34 Maass PG, Wirth J, Aydin A. et al. A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to Brachydactyly Type E. Hum Mol Genet 2010; 19: 848-860
• 35 Klopocki E, Hennig BP, Dathe K. et al. Deletion and point mutations of PTHLH cause brachydactyly type E. Am J Hum Genet 2010; 86: 434-439
• 36 Thomas-Teinturier C, Pereda A, Garin I. et al. Report of two novel mutations in PTHLH associated with brachydactyly type E and literature review. Am J Med Genet A 2016; 170: 734-742
• 37 Wang J, Wang Z, An Y. et al. Exome sequencing reveals a novel PTHLH mutation in a Chinese pedigree with brachydactyly type E and short stature. Clin Chim Acta 2015; 446: 9-14
• 38 Jamsheer A, Sowinska-Seidler A, Olech EM. et al. Variable expressivity of the phenotype in two families with brachydactyly type E, craniofacial dysmorphism, short stature and delayed bone age caused by novel heterozygous mutations in the PTHLH gene. J Hum Genet 2016; 61: 457-461
• 39 Pereda A, Garzon-Lorenzo L, Garin I. et al. The p.R56* mutation in PTHLH causes variable brachydactyly type E. Am J Med Genet A 2017; 173: 816-819
• 40 Reyes M, Bravenboer B, Jüppner H. A Heterozygous splice-site mutation in PTHLH causes autosomal dominant shortening of metacarpals and metatarsals. J Bone Miner Res 2019; 34: 482-489
• 41 Collinson M, Leonard SJ, Charlton J. et al. Symmetrical enchondromatosis is associated with duplication of 12p11.23 to 12p11.22 including PTHLH. Am J Med Genet A 2010; 152A: 3124-3128
• 42 Silve C. A Cup Half-Full or Half-Empty? When PTHrP Levels Matter. IBMS BoneKEy. 2010; 7 http://www.bonekey-ibms.org/cgi/content/full/ibmske;7/9/325 325–332
• 43 Ablow RC, Hsia YE, Brandt IK. Acrodysostosis coinciding with pseudohypoparathyroidism and pseudo-pseudohypoparathyroidism. AJR Am J Roentgenol 1977; 128: 95-99
• 44 Davies SJ, Hughes HE. Familial acrodysostosis: can it be distinguished from Albright’s hereditary osteodystrophy?. Clin Dysmorphol. 1992; 1: 207-215
• 45 Tasken K, Skalhegg BS, Tasken KA. et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997; 31: 191-204
• 46 Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: Framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990; 59: 971-1005
• 47 Taylor SS, Kim C, Cheng CY. et al. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim Biophys Acta 2008; 1784 (01) 16-26
• 48 Linglart A, Menguy C, Couvineau A. et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011; 364: 2218-2226
• 49 Silve C, Clauser E, Linglart A. Acrodysostosis. Horm Metab Res 2012; 44: 749-758
• 50 Silve C, Le-Stunff C, Motte E. et al. Acrodysostosis syndromes. BoneKEy 2012; 11: 21
• 51 Elli FM, Bordogna P, de Sanctis L. et al. Screening of PRKAR1A and PDE4D in a Large Italian series of patients clinically diagnosed with Albright hereditary osteodystrophy and/or pseudohypoparathyroidism. J Bone Miner Res 2016; 31: 1215-1224
• 52 Rhayem Y, Le Stunff C, Abdel Khalek W. et al. Functional characterization of PRKAR1A mutations reveals a unique molecular mechanism causing acrodysostosis but multiple mechanisms causing carney complex. J Biol Chem 2015; 290: 27816-27828
• 53 Lee H, Graham JM, Rimoin DL. et al. Exome sequencing identifies PDE4D mutations in acrodysostosis. Am J Hum Genet 2012; 90: 746-751
• 54 Michot C, Le Goff C, Goldenberg A. et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet 2012; 90: 740-745
• 55 Linglart A, Fryssira H, Hiort O. et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab 2012; 97: E2328-E2338
• 56 Lindstrand A, Grigelioniene G, Nilsson D. et al. Different mutations in PDE4D associated with developmental disorders with mirror phenotypes. J Med Genet 2014; 51: 45-54
• 57 Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370 1-18
• 58 Kaname T, Ki CS, Niikawa N. et al. Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. Cell Signal 2014; 26: 2446-2459
• 59 Lynch DC, Dyment DA, Huang L. et al. Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat 2013; 34: 97-102
• 60 Michot C, Le Goff C, Blair E. et al. Expanding the phenotypic spectrum of variants in PDE4D/PRKAR1A: From acrodysostosis to acroscyphodysplasia. Eur J Hum Genet 2018; 26: 1611-1622
• 61 Cedervall P, Aulabaugh A, Geoghegan KF. et al. Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4. Proc Natl Acad Sci USA 2015; 112: E1414-E1422
• 62 Briet C, Pereda A, Le Stunff C. et al. Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3. Hum Mol Genet 2017; 26: 3883-3894
• 63 Bilginturan N, Zileli S, Karacadag S. et al. Hereditary brachydactyly associated with hypertension. J Med Genet 1973; 10: 253-259
• 64 Maass PG, Aydin A, Luft FC. et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet 2015; 47: 647-653
• 65 Boda H, Uchida H, Takaiso N et al. A PDE3A mutation in familial hypertension and brachydactyly syndrome. J Hum Genet 2016;
• 66 Renkema KY, Westermann JM, Nievelstein RAJ. et al. PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome). Hypertens Res 2018; 41: 981-988
• 67 Pereda A, Garin I, Garcia-Barcina M. et al. Brachydactyly E: Isolated or as a feature of a syndrome. Orphanet J Rare Dis 2013; 8: 141
• 68 Karaca A, Reyes M, Shumate LT. et al. Severe brachydactyly and short stature resulting from a novel pathogenic TRPS1 variant within the GATA DNA-binding domain. Bone 2019; 123: 153-158
• 69 Grigelioniene G, Eklof O, Ivarsson SA. et al. Mutations in short stature homeobox containing gene (SHOX) in dyschondrosteosis but not in hypochondroplasia. Hum Genet 2000; 107: 145-149
• 70 Phelan MC, Rogers RC, Clarkson KB. et al. Albright hereditary osteodystrophy and del(2) (q37.3) in four unrelated individuals. Am J Med Genet 1995; 58: 1-7
• 71 Williams SR, Aldred MA, Der Kaloustian VM. et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 2010; 87: 219-228
• 72 Wein MN, Liang Y, Goransson O. et al. SIKs control osteocyte responses to parathyroid hormone. Nat Commun 2016; 7: 13176
• 73 Elli FM, deSanctis L, Maffini MA. et al. Association of GNAS imprinting defects and deletions of chromosome 2 in two patients: Clues explaining phenotypic heterogeneity in pseudohypoparathyroidism type 1B/iPPSD3. Clin Epigenetics 2019; 11: 3
• 74 Lee K, Deeds JD, Segre GV. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acid during fetal development of rats. Endocrinology 1995; 136: 453-463
• 75 Riccardi D, Lee WS, Lee K. et al. Localization of the extracellular Ca(2+)-sensing receptor and PTH/PTHrP receptor in rat kidney. Am J Physiol 1996; 271: F951-F956
• 76 Silve C, Jüppner H. In: Bilezikian J, ed Principles of Bone Biology. San Diego: Academic Press; 2019
• 77 Marouli E, Graff M, Medina-Gomez C. et al. Rare and low-frequency coding variants alter human adult height. Nature 2017; 542: 186-190